<DOC>
	<DOCNO>NCT00383474</DOCNO>
	<brief_summary>This phase I trial study side effect best dose tipifarnib bortezomib treat patient acute leukemia chronic myelogenous leukemia blast phase . Tipifarnib bortezomib may stop growth cancer cell block enzymes need cell growth . Giving tipifarnib together bortezomib may kill cancer cell .</brief_summary>
	<brief_title>Tipifarnib Bortezomib Treating Patients With Acute Leukemia Chronic Myelogenous Leukemia Blast Phase</brief_title>
	<detailed_description>PRIMARY OBJECTIVE : I . Determine dose-limiting toxicity maximum tolerate dose tipifarnib bortezomib patient relapse refractory acute myeloid leukemia , acute lymphoblastic leukemia , chronic myeloid leukemia blast phase . SECONDARY OBJECTIVES : I . Determine effect regimen farnesyltransferase proteasome inhibition peripheral blood mononuclear cell patient . II . Determine clinical efficacy regimen patient . OUTLINE : This dose-escalation study . Patients receive bortezomib IV 3-5 second day 1 , 4 , 8 , 11 oral tipifarnib twice daily day 1-14 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Patients partial response stable disease may continue therapy beyond 6 course discretion investigator . Cohorts 3-6 patient receive escalate dos bortezomib tipifarnib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Blood collect periodically protein expression study . Bone marrow aspirate obtain baseline examine immunohistochemistry Ki-67 activity .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Hypereosinophilic Syndrome</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Eosinophilic , Acute</mesh_term>
	<mesh_term>Leukemia , Basophilic , Acute</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Meets 1 follow diseasespecific criterion : Relapsed disease = &lt; 2 prior chemotherapy regimen ( consolidation therapy exclude ) Primaryinduction failure Previously untreated deemed unfit refuse cytotoxic chemotherapy No hyperleukocytosis ( leukemic blast &gt; = 30,000/mm^3 ) No acute promyelocytic leukemia ( M3 ) No active CNS leukemia SGOT SGPT = &lt; 2 time upper limit normal ( ULN ) Bilirubin normal Creatinine = &lt; 1.5 time ULN No uncontrolled hypertension , congestive heart failure , angina pectoris , ventricular dysrhythmias Not pregnant nursing Negative pregnancy test No uncontrolled disseminate intravascular coagulation Fertile patient must use effective contraception Hormonal contraception must initiate â‰¥ 1 month prior study entry No active graftvshost disease No active uncontrolled infection No intrinsic impair organ function No known allergy imidazole drug No neuropathy &gt; = grade 1 No know hypersensitivity bortezomib , tipifarnib , boron , mannitol No physical psychiatric condition would preclude study participation , include poorly control psychosis At least 48 hour since prior hydroxyurea No prior tipifarnib , bortezomib , investigational proteasomal inhibitor No concurrent radiotherapy , chemotherapy , immunotherapy No concurrent enzymeinducing antiepileptic medication ( e.g. , phenytoin , phenobarbital , carbamazepine ) ECOG performance status 02 LVEF &gt; = 40 % Pathologically confirm diagnosis 1 following : Acute myeloid leukemia Acute lymphoblastic leukemia Chronic myelogenous leukemia blast phase</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>